Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting — Stella

Home/Exudative Macular Degeneration/

View on ClinicalTrials.gov

Recruiting

Back to Exudative Macular Degeneration trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Austria

Department of Ophthalmology, Medical University of Vienna, Austria, Vienna, State of Vienna

Key details

Phase

Post-approval study

Sponsor

Medical University of Vienna

Enrollment target

~290 participants

Started

March 2021

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 100 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.